Wednesday, 27 December 2017

GOOD SYMPTOM RELIEF WITH MVP CHEMOTHERAPY.

GOOD SYMPTOM RELIEF WITH MVP CHEMOTHERAPY. Over the course of more than 10 years, 39 patients with advanced inoperable malignant mesothelioma were treated with palliative mitomycin-C, vinblastine and cisplatin (MVP) chemotherapy. Eight of 39 patients (20%) achieved an objective partial response with a median duration of nine months; only five patients had progression of disease during chemotherapy. Twenty-four of 39 (62%) had an overall improvement in their symptomology with particularly good responses for pain.

These benefits were independent of performance status. Resolution of symptoms was achieved in all responding patients within two treatment cycles. The treatment was well tolerated with only four patients developing grade 3 leukopenia (white blood cell reduction) and three with grade 3 nausea. MVP is a well tolerated regimen and its use in malignant mesothelioma provides useful symptomatic relief. These results should be the basis for further trials of MVP in the management of malignant mesothelioma with symptom control as a principal endpoint. "Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma", Middleton, et al., Annals of Oncology, 9(3):269-73, March 1998. Over the course of more than 10 years, 39 patients with advanced inoperable malignant mesothelioma were treated with palliative mitomycin-C, vinblastine and cisplatin (MVP) chemotherapy. Eight of 39 patients (20%) achieved an objective partial response with a median duration of nine months; only five patients had progression of disease during chemotherapy. Twenty-four of 39 (62%) had an overall improvement in their symptomology with particularly good responses for pain. These benefits were independent of performance status.

Resolution of symptoms was achieved in all responding patients within two treatment cycles. The treatment was well tolerated with only four patients developing grade 3 leukopenia (white blood cell reduction) and three with grade 3 nausea. MVP is a well tolerated regimen and its use in malignant mesothelioma provides useful symptomatic relief. These results should be the basis for further trials of MVP in the management of malignant mesothelioma with symptom control as a principal endpoint. "Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma", Middleton, et al., Annals of Oncology, 9(3):269-73, March 1998.

GOOD SYMPTOM RELIEF WITH MVP CHEMOTHERAPY. Rating: 4.5 Diposkan Oleh: ABD KADIR Rusdi

Categories

cancer (53) women (2)

Popular Posts